Latest Blueprint Medicines Stories
-- Journal of Clinical Investigation article highlights Blueprint Medicines' focus on exploiting untapped potential in well-validated field of kinase drug discovery -- CAMBRIDGE, Mass., May
CAMBRIDGE, Mass., May 5, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC) today announced the closing of its initial public offering of 9,367,708 shares of common stock at a public offering
CAMBRIDGE, Mass., April 8, 2015 /PRNewswire/ -- Blueprint Medicines today announced it will present new preclinical data on its drug candidate BLU-285 in gastrointestinal stromal tumors (GIST), as
- On track to file IND for BLU-554 and initiate clinical studies by mid-2015 - CAMBRIDGE, Mass., March 16, 2015 /PRNewswire/ -- Blueprint Medicines today announced publication of the discovery
- Collaboration combines Blueprint Medicines' kinase-focused drug discovery platform with Alexion's experience developing and commercializing therapies for severe and life-threatening disorders -
CAMBRIDGE, Mass., Feb.
CAMBRIDGE, Mass., Jan.
SAN FRANCISCO, Dec.
- Builds on Company's novel discovery of several kinase fusion genes in cancer - CAMBRIDGE, Mass., Nov.
-Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors- CAMBRIDGE, Mass.,
- A handkerchief.
- Specifically— The legendary sweat-cloth; the handkerchief of St. Veronica, according to tradition miraculously impressed with the mask of Christ; also, the napkin about Christ's head (Johu xx. 7).
- In general, any miraculous portrait of Christ.